Apricus Biosc Inc (APRI) 0.33 $APRI Apricus Bio
Post# of 273257
Posted On: 09/03/2016 3:13:19 AM
Apricus Biosc Inc (APRI) 0.33 $APRI
Apricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros(R) to Ferring Pharmaceuticals
Globe Newswire - Mon Aug 15, 6:00AM CDT
SAN DIEGO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Company's new partner in the United Kingdom, has received the United Kingdom marketing authorization for Vitaros(R).
APRI: 0.33 (-0.01)
Apricus Biosciences Announces Completion of Transfer of Vitaros(R) German Marketing Authorization to Ferring Pharmaceuticals
Globe Newswire - Wed Aug 10, 6:00AM CDT
SAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Company's new partner in Germany, has received the German marketing authorization for Vitaros(R).
APRI: 0.33 (-0.01)
Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results
GlobeNewswire - Thu Aug 04, 3:01PM CDT
Strategic Focus on Growing Global Vitaros Revenue and Achieving Profitability in 2017
APRI: 0.33 (-0.01)
Apricus Biosciences to Present at the Canaccord Genuity 36th Annual Growth Conference
Globe Newswire - Wed Aug 03, 6:00PM CDT
SAN DIEGO, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016, at 1:30 p.m. Eastern Time. The conference will be held at the InterContinental in Boston, MA. Mr. Pascoe will provide an update on the Company's strategy and development plans surrounding Vitaros(R).
APRI: 0.33 (-0.01)
Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call
Globe Newswire - Mon Aug 01, 6:00AM CDT
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's second quarter 2016 financial results will be released on Thursday, August 4, 2016 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, August 4, 2016, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
APRI: 0.33 (-0.01)
Biocom Appoints New Directors to its Board
PR Newswire - Tue Jun 07, 11:01AM CDT
Biocom, the association representing the Southern California life science community, today announced the appointment of 13 new directors to its board, including the appointment of Charles Dadswell, senior vice president and general counsel for Illumina, and Rich Pascoe, chief executive officer of Apricus Biosciences, to the executive committee of Biocom's board. In addition, Biocom announced that Magda Marquet, Ph.D., co-founder of Ajinomoto Althea and AltheaDx, and Brent D. Jacobs, executive director in the global life sciences practice group at Cushman & Wakefield, were named as life directors, a prestigious and special class of director.
APRI: 0.33 (-0.01)
ARIAD (ARIA) Commences Phase I/II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 4:05PM CDT
ARIAD (ARIA) announced the initiation of a phase I/IIstudy on AP32788 for the treatment of non-small cell lung cancer with specific mutations in EGFR or HER2.
APRI: 0.33 (-0.01), JNP: 5.56 (+0.05), ARIA: 10.12 (-0.07)
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 36.56 (-0.99), ARQL: 1.40 (unch), APRI: 0.33 (-0.01), RPRX: 2.00 (unch)
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 36.56 (-0.99), JAZZ: 120.84 (-2.47), ARQL: 1.40 (unch), APRI: 0.33 (-0.01)
Apricus reports 1Q loss
Automated Insights - Mon May 09, 6:49AM CDT
SAN DIEGO (AP) _ Apricus Biosciences Inc. (APRI) on Monday reported a loss of $2.5 million in its first quarter.
APRI: 0.33 (-0.01)
Apricus Biosciences Provides Corporate Update and First Quarter Financial Results
Globe Newswire - Mon May 09, 6:00AM CDT
Vitaros(R) U.S. NDA Re-Submission on Schedule for 3Q 2016
APRI: 0.33 (-0.01)
CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 1:44PM CDT
In a release issued under the same headline earlier today by Apricus Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the subhead of the release, "2H 2016" should instead be "Q3 2016."
APRI: 0.33 (-0.01)
Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 6:01AM CDT
Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of Tennessee Graduate School of Medicine
APRI: 0.33 (-0.01)
Apricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros(R) to Ferring Pharmaceuticals
Globe Newswire - Mon Aug 15, 6:00AM CDT
SAN DIEGO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Company's new partner in the United Kingdom, has received the United Kingdom marketing authorization for Vitaros(R).
APRI: 0.33 (-0.01)
Apricus Biosciences Announces Completion of Transfer of Vitaros(R) German Marketing Authorization to Ferring Pharmaceuticals
Globe Newswire - Wed Aug 10, 6:00AM CDT
SAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Ferring Pharmaceuticals, the Company's new partner in Germany, has received the German marketing authorization for Vitaros(R).
APRI: 0.33 (-0.01)
Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results
GlobeNewswire - Thu Aug 04, 3:01PM CDT
Strategic Focus on Growing Global Vitaros Revenue and Achieving Profitability in 2017
APRI: 0.33 (-0.01)
Apricus Biosciences to Present at the Canaccord Genuity 36th Annual Growth Conference
Globe Newswire - Wed Aug 03, 6:00PM CDT
SAN DIEGO, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016, at 1:30 p.m. Eastern Time. The conference will be held at the InterContinental in Boston, MA. Mr. Pascoe will provide an update on the Company's strategy and development plans surrounding Vitaros(R).
APRI: 0.33 (-0.01)
Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call
Globe Newswire - Mon Aug 01, 6:00AM CDT
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's second quarter 2016 financial results will be released on Thursday, August 4, 2016 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, August 4, 2016, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
APRI: 0.33 (-0.01)
Biocom Appoints New Directors to its Board
PR Newswire - Tue Jun 07, 11:01AM CDT
Biocom, the association representing the Southern California life science community, today announced the appointment of 13 new directors to its board, including the appointment of Charles Dadswell, senior vice president and general counsel for Illumina, and Rich Pascoe, chief executive officer of Apricus Biosciences, to the executive committee of Biocom's board. In addition, Biocom announced that Magda Marquet, Ph.D., co-founder of Ajinomoto Althea and AltheaDx, and Brent D. Jacobs, executive director in the global life sciences practice group at Cushman & Wakefield, were named as life directors, a prestigious and special class of director.
APRI: 0.33 (-0.01)
ARIAD (ARIA) Commences Phase I/II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 4:05PM CDT
ARIAD (ARIA) announced the initiation of a phase I/IIstudy on AP32788 for the treatment of non-small cell lung cancer with specific mutations in EGFR or HER2.
APRI: 0.33 (-0.01), JNP: 5.56 (+0.05), ARIA: 10.12 (-0.07)
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 36.56 (-0.99), ARQL: 1.40 (unch), APRI: 0.33 (-0.01), RPRX: 2.00 (unch)
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 36.56 (-0.99), JAZZ: 120.84 (-2.47), ARQL: 1.40 (unch), APRI: 0.33 (-0.01)
Apricus reports 1Q loss
Automated Insights - Mon May 09, 6:49AM CDT
SAN DIEGO (AP) _ Apricus Biosciences Inc. (APRI) on Monday reported a loss of $2.5 million in its first quarter.
APRI: 0.33 (-0.01)
Apricus Biosciences Provides Corporate Update and First Quarter Financial Results
Globe Newswire - Mon May 09, 6:00AM CDT
Vitaros(R) U.S. NDA Re-Submission on Schedule for 3Q 2016
APRI: 0.33 (-0.01)
CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 1:44PM CDT
In a release issued under the same headline earlier today by Apricus Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the subhead of the release, "2H 2016" should instead be "Q3 2016."
APRI: 0.33 (-0.01)
Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 6:01AM CDT
Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of Tennessee Graduate School of Medicine
APRI: 0.33 (-0.01)
(0)
(0)Scroll down for more posts ▼